04:44 AM EST, 11/13/2026 (MT Newswires) -- Berenberg maintained its buy rating on Eli Lilly (LLY.SW, LLY.F), with a price target of $1,570, noting the pharmaceutical giant's full-year 2027 outlook continues to look "strong" ahead of anticipated volume-driven tailwinds. "Continued obesity drug uptake across the US Medicare GLP-1 bridge and Medicaid channels, combined with fast-growing cash pay demand (particularly ex-US), is expected to comfortably more than offset incremental price erosion next year. The imminent US approval of Foundayo in diabetes, and further ex-US market launches, will drive additional volume growth into next year. Lilly will provide an update on R&D progress on 7 December at its Innovation Day in Boston," analysts said after hosting Eli Lilly's Lucas Montarce for its annual chief financial officer series. For the upcoming investor event, the research firm said Eli Lilly will highlight progress across its obesity and non-obesity pipelines. Meanwhile, Montarce told Berenberg that 2027 guidance will be provided alongside 2026 earnings results in early February 2027, not on Innovation Day. Berenberg noted that other near-term catalysts include a first-quarter 2027 US filing for retatrutide in obesity, and upcoming phase 3 readouts next year for Inluriyo in adjuvant breast cancer and Kisunla in pre-clinical Alzheimer's.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.